Answers are grounded in this paper and cite their sources.
AIM: To determine whether astrocyte-derived small extracellular vesicles (sEVs) deliver Serpina3k to recipient neural cells and protect against cerebral ischemia-reperfusion injury (CIRI). METHODS: A mouse transient middle cerebral artery occlusion/reperfusion model was combined with pharmacological inhibition of sEV release, astrocyte-targeted Serpina3k knockdown and intrathecal delivery of astrocyte-derived sEVs. Brain sEV cargo was profiled by label-free proteomics and Transwell co-cultures were subjected to oxygen-glucose deprivation/reoxygenation. Neurological outcomes, infarct volume, apoptosis and inflammatory mediators were assessed, and Serpina3k-interacting proteins were identified by co-immunoprecipitation. RESULTS: Blocking sEV release aggravated neurological deficits, neuronal apoptosis and inflammation. Brain-derived sEVs increased after ischemia-reperfusion and protected neurons against oxygen-glucose deprivation/reoxygenation. Serpina3k was enriched in ischemia-derived sEVs and localized predominantly to astrocytes; astrocytic Serpina3k knockdown reduced sEV-associated Serpina3k and worsened deficits, whereas Serpina3k-deficient sEVs increased neuronal apoptosis, microglial IL-1beta and IL-18 release, infarct volume and Caspase-6/NLRP3 signalling. Serpina3k co-immunoprecipitated with Caspase-6 and Omi/HtrA2. In vivo, Serpina3k-deficient astrocytic sEVs were associated with larger infarct volume, increased Omi/HtrA2 expression and reduced HAX-1 expression. CONCLUSION: Astrocyte-derived sEV-associated Serpina3k is an endogenous protective cargo that limits cerebral ischemia-reperfusion injury by restraining microglial inflammatory activation and neuronal apoptosis.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: